Passage Bio, Inc. (PASG)
NASDAQ: PASG · IEX Real-Time Price · USD
1.240
+0.010 (0.81%)
At close: Apr 24, 2024, 4:00 PM
1.270
+0.030 (2.42%)
After-hours: Apr 24, 2024, 5:42 PM EDT
Passage Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Passage Bio stock have an average target of 9.33, with a low estimate of 5.00 and a high estimate of 14. The average target predicts an increase of 652.42% from the current stock price of 1.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 5, 2024.
Analyst Ratings
The average analyst rating for Passage Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +1,029.03% | Mar 5, 2024 |
| Raymond James | Raymond James | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +303.23% | Nov 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +625.81% | Aug 8, 2023 |
| Raymond James | Raymond James | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +625.81% | May 12, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $18 → $11 | Strong Buy | Maintains | $18 → $11 | +787.10% | Dec 15, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.94M
EPS This Year
-1.21
from -1.86
EPS Next Year
-0.96
from -1.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 4.0M | 13.1M | 109.6M | 323.8M |
| Avg | n/a | 1.9M | 4.8M | 46.2M | 121.8M |
| Low | n/a | n/a | n/a | n/a | 17.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 577.2% | 2,186.6% | 601.2% |
| Avg | - | - | 147.4% | 863.4% | 163.8% |
| Low | - | - | - | - | -61.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.88 | -0.55 | -0.53 | -0.46 | 0.55 |
| Avg | -1.21 | -0.96 | -0.94 | -0.65 | 0.06 |
| Low | -1.44 | -1.62 | -1.45 | -0.81 | -0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.